Pseudoxanthoma Elasticum Epidemiology Forecast 2025-2034

Pseudoxanthoma elasticum (PXE) is a rare condition, with the prevalence ranging from 1 in 40,000 to 1 in 100,000 people. It is more common in women, with a female-to-male ratio of 4:1. The disease usually starts in adolescence or early adulthood, but it can develop at any age. The first clinical signs are usually small yellow papules appearing on the nape and sides of the neck and in flexural areas.

Pseudoxanthoma Elasticum Epidemiology Forecast Report Coverage

The “Pseudoxanthoma Elasticum Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of pseudoxanthoma elasticum. It projects the future incidence and prevalence rates of pseudoxanthoma elasticum across various populations. The study covers age and type as major determinants of the pseudoxanthoma elasticum-affected population. The report highlights patterns in the prevalence of pseudoxanthoma elasticum over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of pseudoxanthoma elasticum in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Pseudoxanthoma Elasticum: Disease Overview

Pseudoxanthoma elasticum (PXE) refers to a rare inherited condition that affects the skin, eyes, and blood vessels. It causes the elastic fibers in these areas to become damaged. One of the first signs of pseudoxanthoma elasticum is small, yellowish bumps on the skin, often around the neck and in skin folds like the elbows and knees. PXE can also lead to problems with vision, as it affects the eyes. It is also reported to cause issues with blood vessels, potentially increasing the risk of heart and circulation problems.

Pseudoxanthoma Elasticum: Treatment Overview

There is currently no cure for pseudoxanthoma elasticum. The treatment approach is focused on managing symptoms and preventing complications. Regular dermatological check-ups are recommended to monitor and treat the skin changes. Moisturizing lotions can help address skin dryness. Dermatologists can remove or treat yellowish bumps if they cause discomfort. Moreover, regular eye exams and cardiovascular monitoring are advised to prevent any severe complications.

Epidemiology

The pseudoxanthoma elasticum epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for pseudoxanthoma elasticum by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for pseudoxanthoma elasticum and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• The prevalence of pseudoxanthoma elasticum is estimated to be between 1 in 40,000 and 1 in 100,000 people, with a higher occurrence in females than males, at a ratio of 4:1, as per the Orphanet. The reason for this female predominance is not fully understood.
• In the general population, the prevalence of pseudoxanthoma elasticum is reported to be between 1 in 25,000 and 56,000 people, according to a review published in Biomedicines (2021).
• About 1 in 50,000 individuals worldwide are affected by pseudoxanthoma elasticum.
• The average age of onset for pseudoxanthoma elasticum is 13 years, but it can develop at any age from infancy to the age of 70 or older. Most new cases occur between the ages of 10 and 15.

Country-wise Pseudoxanthoma Elasticum Epidemiology

The pseudoxanthoma elasticum epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of pseudoxanthoma elasticum varies significantly between countries due to differences in genetic factors, access to healthcare, and diagnostic practices. The condition is likely to be more common in countries with higher rates of consanguinity (marriage between relatives). As per a nationwide population-based cohort study (2011-2020) conducted in Japan, 1,020 cases of pseudoxanthoma elasticum were identified. The incidence rate of PXE was reported to be 0.08 per 100,000 person-years, and the prevalence on October 1, 2020, was 0.83 per 100,000 persons.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of pseudoxanthoma elasticum based on several factors.
• The Pseudoxanthoma Elasticum Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of pseudoxanthoma elasticum are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of pseudoxanthoma elasticum epidemiology in the 8 major markets?
• What will be the total number of patients with pseudoxanthoma elasticum across the 8 major markets during the forecast period?
• What was the country-wise prevalence of pseudoxanthoma elasticum in the 8 major markets in the historical period?
• Which country will have the highest number of pseudoxanthoma elasticum patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of pseudoxanthoma elasticum during the forecast period of 2025-2034?
• What are the currently available treatments for pseudoxanthoma elasticum?
• What are the disease risks, signs, symptoms, and unmet needs of pseudoxanthoma elasticum?

This product will be delivered within 3-5 business days.